Chinese biotech giant WuXi AppTec raised its full-year revenue guidance for 2026, after its net profit surged 62.4% and revenue grew 38.6% in the first nine months, driven by strong demand for drug development and manufacturing services. According to a filing with the Hong Kong Stock Exchange, WuXi AppTec's net profit reached 19.16 billion yuan (approximately $2.87 billion) for the nine months ended September 30, up from 11.8 billion yuan in the same period last year. Revenue for the same period increased to 45.54 billion yuan, up from 32.86 billion yuan in the prior year. The Shanghai-based company raised its full-year revenue forecast to 61 billion to 61.9 billion yuan, from a previous estimate of 58.5 billion to 60.5 billion yuan, and expects revenue from continuing operations to grow 40% to 42%, up from its previous forecast of 35% to 39%.